Neuroprotective action of diazepam at very low and moderate doses in Alzheimer's disease model rats.
Acetylcholine
/ metabolism
Alzheimer Disease
/ drug therapy
Animals
Astrocytes
/ drug effects
Cerebral Cortex
/ drug effects
Diazepam
/ administration & dosage
Dose-Response Relationship, Drug
Gene Expression Regulation
/ drug effects
Gliosis
/ drug therapy
Glutamate Decarboxylase
/ metabolism
Hippocampus
/ drug effects
Male
Memory Disorders
/ drug therapy
Neuroprotective Agents
/ administration & dosage
Random Allocation
Rats, Wistar
Synaptophysin
/ metabolism
gamma-Aminobutyric Acid
/ metabolism
Alzheimer's disease
Cognitive impairment
Diazepam
Neuroinflammation
Neuroprotection
Streptozocin
Journal
Neuropharmacology
ISSN: 1873-7064
Titre abrégé: Neuropharmacology
Pays: England
ID NLM: 0236217
Informations de publication
Date de publication:
01 2019
01 2019
Historique:
received:
16
05
2018
revised:
31
10
2018
accepted:
03
11
2018
pubmed:
9
11
2018
medline:
5
3
2019
entrez:
9
11
2018
Statut:
ppublish
Résumé
Early manifestations of Alzheimer's disease (AD) include neuroinflammation, disrupted neurotransmission and cognitive deficits. Impairment of the GABAergic system is essentially involved in the pathogenesis of AD. Traditionally, agonists of GABA
Identifiants
pubmed: 30408486
pii: S0028-3908(18)30840-2
doi: 10.1016/j.neuropharm.2018.11.003
pii:
doi:
Substances chimiques
Neuroprotective Agents
0
Synaptophysin
0
Syp protein, rat
0
gamma-Aminobutyric Acid
56-12-2
Glutamate Decarboxylase
EC 4.1.1.15
glutamate decarboxylase 1
EC 4.1.1.15
Acetylcholine
N9YNS0M02X
Diazepam
Q3JTX2Q7TU
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
319-326Informations de copyright
Copyright © 2018 Elsevier Ltd. All rights reserved.